Search for a trial

The Gaia study

The primary objective is to assess diagnostic accuracy of MRDTI/BTI for first and recurrent CVT in patients referred for MRI/MRV in the setting of routine clinical setting. The secondary objectives are to optimize MRDTI/BTI sequences for imaging…

Hydra study

To prospectively validate the safety and efficiency of management according to the YEARS algorithm to safely rule out clinically suspected PE in patients with active malignancy to be compared with `standard' management by CTPA alone in a…

Brain Outcome after Cardiac Arrest - prediction

Primary objective Primary objective is to create a prediction model based on early clinical screening of motor, cognitive, and emotional disturbances to predict restrictions in participation at one year after cardiac arrest in patients that have…

Antigen specific T cells in advanced human atherosclerosis

The primary objective of this study is to measure the number of antigen specific T-cells in the plaque and in blood, and investigate whether these parameters correlate with the phenotype of the atherosclerotic plaque. Secondary objectives are: 1)…

Clinical outcomes and cost-effectiveness of a diagnostic and treatment strategy of upfront CTCA plus selective non-invasive functional imaging compared with standard care in patients with chest pain and suspected coronary artery disease

This strategy will result in a reduction reduce the incidence of major adverse cardiovascular events (MACE) defined as death or non-fatal myocardial infarction and appear more efficient than care as usual.

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples in a first line setting from patients diagnosed with metastatic Colorectal Cancer (mCRC) to determine the KRAS G12C mutation status as part of the inclusion criteria into the Amgen Phase III clinical trial (Protocol No 20210081) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…

DIAMONDS

The objective of this study is to determine the ability of respiratory EMG measurements with a wearable to …

Clinical Performance Study Protocol for Use of VENTANA PD-L1 (SP263)
CDx Assay in [redacted]

The objective of this study is to establish the clinical performance of VENTANA PD-L1 (SP263) CDx Assay as a companion diagnostic (CDx) for the identification of patients with NSCLC who may benefit from treatment with [redacted]. …